Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

Fifteen-year-old Dominic Henriquez from Prosper, Texas, is bringing hope to boys like him who live with Hunter syndrome, a rare genetic disorder that primarily affects males. Dominic’s journey ...

When is the Monster Hunter Wilds release date? Following the much-lauded migration 0f Monster Hunter onto PC in recent years, we’re sharpening our blades in preparation for the next installment ...

With Monster Hunter Wilds releasing in just over a month, it's worth studying the confirmed monsters we'll be hunting across the Forbidden Lands. Preparation is, after all, half of the hunter's ...

Aaron Taylor-Johnson in "Kraven the Hunter." Kraven the Hunter—the Marvel movie bust starring Aaron Taylor-Johnson and Russell Crowe—is coming soon to digital streaming. Kraven the Hunter ...

RegenxBio said Tuesday that Kyoto, Japan’s Nippon Shinyaku Co. Ltd. will develop and commercialize its one-time gene therapies for Hunter syndrome and Hurler syndrome, both affecting children.

"Kraven the Hunter" partial poster featuring Aaron Taylor-Johnson. Kraven the Hunter—the Marvel box office bust starring Aaron Taylor-Johnson and Russell Crowe—debuts on digital streaming this ...

The Monster Hunter series first launched on PlayStation 2 in 2004 and has since won over many fans, evolving at a dizzying pace alongside new developments in hardware. While it may sound like a ...